SEC Form 4
------------

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average I	burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	STAT

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Jones James (Last) (First) (Middle) 1600 WEST END AVENUE, SUITE 1300		on*	2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [ CPIX ]		tionship of Reporting Perso all applicable) Director Officer (give title	on(s) to Issuer 10% Owner Other (specify				
		,	3. Date of Earliest Transaction (Month/Day/Year) 09/05/2023		below)	below)				
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person					
NASHVILLE	TN	37203			Form filed by More than Person	0				
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication							
			X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 - Non-Derivative Securities Acquireu, Disposed of, of Deriencially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed O 5)	s Acquire f (D) (Inst	d (A) or r. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock	09/05/2023		L	v	<b>65</b> <sup>(1)</sup>	A	\$1.68	28,105	D		
Common Stock	09/06/2023		L	v	<b>65</b> <sup>(1)</sup>	A	\$1.65	28,170	D		
Common Stock	09/07/2023		L	v	<b>65</b> <sup>(1)</sup>	A	\$1.68	28,235	D		
Common Stock	09/08/2023		L	v	<b>65</b> <sup>(1)</sup>	A	\$1.68	28,300	D		
Common Stock	09/11/2023		L	v	<b>65</b> <sup>(1)</sup>	A	\$1.72	28,365	D		
Common Stock	09/12/2023		L	v	<b>65</b> <sup>(1)</sup>	Α	\$1.76	28,430	D		
Common Stock	09/13/2023		L	v	<b>65</b> <sup>(1)</sup>	Α	\$1.83	28,495	D		
Common Stock	09/14/2023		L	v	65(1)	Α	\$1.84	28,560	D		
Common Stock	09/15/2023		L	v	23(1)	A	\$1.82	28,583	D		
Common Stock	09/18/2023		L	v	55 <sup>(1)</sup>	Α	\$2.03	28,638	D		
Common Stock	09/19/2023		L	v	55 <sup>(1)</sup>	Α	\$2.12	28,693	D		
Common Stock	09/20/2023		L	v	55 <sup>(1)</sup>	A	\$2.14	28,748	D		
Common Stock	09/21/2023		L	v	55 <sup>(1)</sup>	Α	\$2.28	28,803	D		
Common Stock	09/22/2023		L	v	55 <sup>(1)</sup>	A	\$2.29	28,858	D		
Common Stock	09/25/2023		L	v	55 <sup>(1)</sup>	A	\$2.24	28,913	D		
Common Stock	09/26/2023		L	V	55 <sup>(1)</sup>	Α	\$2.07	28,968	D		
Common Stock	09/27/2023		L	V	55 <sup>(1)</sup>	A	\$1.98	29,023	D		
Common Stock	09/28/2023		L	v	55 <sup>(1)</sup>	A	\$1.96	29,078	D		
Common Stock	09/29/2023		L	v	55 <sup>(1)</sup>	A	\$1.9	29,133	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		Amount of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023.

James Jones by /s/ John Hamm as attorney-in-fact

10/03/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.